Envestnet Asset Management’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Envestnet Asset Management’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,059	Closed	-$205K	–	4029
2022 Q4	$205K	Sell	4,059 -78	-2%	-$4.02K	﹤0.01%	3651
2022 Q3	$208K	Buy	+4,137	New	+$233K	﹤0.01%	3560
2022 Q1	–	Sell	-7,269	Closed	-$577K	–	3978
2021 Q4	$577K	Sell	7,269 -1,475	-17%	-$124K	﹤0.01%	2980
2021 Q3	$777K	Buy	+8,744	New	+$819K	﹤0.01%	2709

Other funds holding GNOM

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

OCM

One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Lido Advisors Los Angeles, California $32.7B AUM 19.2% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

PFG

Prosperity Financial Group San Ramon, California $271M AUM 30.27% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MIG

McGuire Investment Group Wakefield, Rhode Island $885M AUM 47.78% 1-Year Est. Return

Envestnet Asset Management's GNOM Position: Q1 2023 in Review

Envestnet Asset Management sold out of Global X Genomics & Biotechnology ETF (GNOM) in Q1 2023, closing a stake of 4,059 shares — an estimated $205K sold.

Envestnet Asset Management first reported a position in GNOM in Q3 2021 and held it in 4 quarters. The position peaked at $777K in Q3 2021. 63 funds tracked by Wall St. Rank hold GNOM as of Q1 2023.

Envestnet Asset Management reported no remaining Global X Genomics & Biotechnology ETF position as of Q1 2023 after selling out during the quarter.
Envestnet Asset Management sold 4,059 Global X Genomics & Biotechnology ETF shares in Q1 2023, an estimated $205K.
Envestnet Asset Management first reported a position in Global X Genomics & Biotechnology ETF in Q3 2021 and held it in 4 quarters.
Envestnet Asset Management's Global X Genomics & Biotechnology ETF position peaked at $777K in Q3 2021.
63 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q1 2023.

Based on Envestnet Asset Management's 13F filing for Q1 2023, filed 11 May 2023.